pronounced permeabilizing effect of tobramycin in combination with imipenem leading to extensive outer membrane disruption, higher periplasmic imipenem concentrations and rapid upregulation of inducible AmpC b-lactamase in P. aeruginosa.
J Antimicrob Chemother 2019; 74: 271-273 doi:10.1093/jac/dky411 Advance Access publication 8 October 2018 Alterations in transmembrane pressures during continuous venovenous haemofiltration significantly contribute to the pharmacokinetic variability of meropenem: a case series of three patients Sir, Meropenem is a broad-spectrum carbapenem b-lactam antibiotic that is removed via continuous venovenous haemofiltration 
(CVVH).
1 A low molecular weight (437.5 Da), low protein-bound fraction (,2%) and volume of distribution (V) ,0.3 L/kg are associated with significant CVVH clearance.
1,2 The likelihood of meropenem crossing the haemofilter membrane is expressed by the sieving coefficient (SC) and is defined as the ratio of meropenem concentration in the ultrafiltrate to the pre-filter plasma concentration. 2, 3 SC values between 0.63 and 1.17 have been reported. [4] [5] [6] A critical parameter that governs SC is the transmembrane pressure that may vary with operation conditions. 7 However, meropenem doses during CVVH do not consider differences in pharmacokinetic (PK) variability owing to changes in transmembrane pressure and meropenem sieving. 2 This study assessed the relationship between transmembrane pressure changes and extracorporeal removal of meropenem during CVVH.
ICU patients with a clinical diagnosis of acute kidney injury (KDIGO stage 3) requiring CVVH were eligible for inclusion. Meropenem was administered via continuous intravenous infusion (CII). 8 Patient A received 2000 mg/day meropenem via CII after an intravenous loading dose of 1000 mg. Patients B and C were treated with 3000 mg/day meropenem via CII after a loading dose of 1000 mg. 1, 4, 9 Renal replacement via CVVH was performed.
3 CVVH (PRISMAFLEX system, Gambro V R ) was conducted using the AN69ST haemofilter with a surface area of 1 m 2 . A regional citrate anticoagulation CVVH protocol using an 18 mM citrate solution (Prismocitrate V R ) with a phosphate-containing replacement fluid (Phoxilium V R ) was used to prevent circuit and filter clotting. 3 The blood flow and net ultrafiltrate rates were set at 180 and 0 mL/min, respectively. Prismocitrate V R 18/0 at 1440 mL/h pre-filter and Phoxilium V R at 1600 mL/h were infused at pre-filter and post-filter dilutions, respectively, with an effluent flow rate of 3040 mL/h. CVVH settings were constant throughout the CVVH sessions.
To determine the steady-state PK of meropenem, plasma, pre-filter, post-filter, ultrafiltrate and urine samples were collected at three different timepoints over 24 h and stored at #80 C until batch-wise analysis. Meropenem was measured using validated UPLC-tandem MS. PK parameters included steady-state plasma concentration (C ss ) , total body clearance (CL TOTAL ), clearance by CVVH (CL CVVH ), V, residual renal clearance and elimination rate constant (k el ). 3 The PK parameters were calculated and modulated using the Mw/Pharm V R 3.81 software. A one-compartment model was applied using currently collected data. Operational characteristics of CVVH and transmembrane pressure as measures of convection were monitored and the ultrafiltrate pump rate (UFR; mL/kg/h) and filtration fraction (FF; %) were calculated. Finally, meropenem CL CVVH was plotted against transmembrane pressure (Figure 1 ).
Three male patients (A, B and C) fulfilled the inclusion criteria. All patients were diagnosed with septic shock due to intraabdominal infection and required mechanical ventilation. Figure 1 . The UFR and FF were 34, 40 and 38 mL/kg/ h and 39%, 38% and 36%, respectively. Filter survival at 72 h was 100% with no obvious signs of filter clotting. We observed an unexpected large variability in SC ranging between 0.45 and 0.96 and documented that transmembrane pressures during CVVH treatment were extremely high and inversely correlated to CL CVVH ( Figure 1 ) (P , 0.01).
The increase in transmembrane pressures over time caused by coagulative occlusion and the blocking of pores changed the properties of the filter membrane resulting in a decline in filter efficacy and lower SCs. Therefore, transmembrane pressure is an important determinant of PK variability during extracorporeal meropenem clearance. Administering 2000 and 3000 mg/day of meropenem via CII resulted in sufficient plasma drug concentrations for treating susceptible bacteria (MIC 2 mg/L) using a target plasma concentration of .4% the MIC. 1 Hence, an increase in CVVH transmembrane pressure is an important determinant of PK variability. Despite considerable inter-patient variability in terms of meropenem CL CVVH , the appropriate time above the MIC (100% fT .4% the MIC) can be achieved by administering 2000-3000 mg/24 h via CII. Another issue that emerges from our findings is the risk of neurotoxicity due to higher meropenem levels. 10 Further studies are required to establish this. Real-time prospective therapeutic drug monitoring of meropenem should include transmembrane pressure and real-time SC to correct for the loss of CVVH efficiency or prevent toxic dose regimens. 
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Sir, In recent years, medicine shortages in healthcare services have become a common occurrence and pose significant challenges to prescribers and pharmacists. Reasons for medicine shortages are many, including manufacturing issues, product recalls or unavailability of raw materials. 1 Results of a point prevalence survey of medicine shortages in Australian hospitals conducted in April 2017 revealed that 95% of participating hospitals experienced a shortage in the preceding 12 months and the most frequently reported shortages were antimicrobials. 2 The prescribing patterns and economic consequences of these antimicrobial shortages in Australian hospitals are ill-defined. Supplies of piperacillin/tazobactam and gentamicin, two frequently used antibiotics, were interrupted to Australian hospitals in September and October 2017, respectively. We evaluated the impact of these shortages on hospital antibiotic use and associated costs.
A retrospective review comparing the inpatient use (excluding hospital-in-the-home) of alternative antibiotics, 3 months preshortage (July-September 2017), 3 months during the shortage (October-December 2017) and 3 months post-shortage (JanuaryMarch 2018), was undertaken at Austin Health, a tertiary teaching hospital in Victoria. Costs of antibiotics were also analysed before and during the shortage periods. A hospital-wide contingency plan recommended alternatives to piperacillin/tazobactam, mainly intravenous amoxicillin/clavulanate and cefepime, based on clinical indication (Table S1 , available as Supplementary data at JAC Online). Shortage of gentamicin also occurred; however, this only lasted for 1 week; amikacin was temporarily used as a substitute where indicated, e.g. directed Gram-negative therapy. Aggregate antibiotic use data, expressed as days of therapy (DOT) per 1000
